Non-enzymatic dissociation of human mesenchymal stromal cells improves chemokine-dependent migration and maintains immunosuppressive function

Cytotherapy

Volumn 16, Issue 4, 2014, Pages 545-559

  Garg, Abhilok ^a   Houlihan, Diarmaid D ^a   Aldridge, Victoria ^a   Suresh, Shankar ^a   Li, Ka Kit ^a   King, Andrew L ^a   Sutaria, Rupesh ^a   Fear, Janine ^a   Bhogal, Ricky H ^a   Lalor, Patricia F ^a   Newsome, Philip N ^a  

^a University of Birmingham   (United Kingdom)

Author keywords

Chemokine receptors; Differentiation; Immune suppression; Mesenchymal stromal cells; Migration

Indexed keywords

CHEMOKINE; EDETIC ACID; MACROPHAGE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; STROMAL CELL DERIVED FACTOR 1;

APOPTOSIS; ARTICLE; AUTOPHAGY; CD3+ CD4+ CD25- T LYMPHOCYTE; CELL DIFFERENTIATION; CELL MIGRATION; CELL VIABILITY; CONTROLLED STUDY; DISSOCIATION; HUMAN; HUMAN CELL; IMMUNOMODULATION; INTERMETHOD COMPARISON; LYMPHOCYTE PROLIFERATION; MESENCHYMAL STROMA CELL; MULTIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE;

CHEMOKINE RECEPTORS; DIFFERENTIATION; IMMUNE SUPPRESSION; MESENCHYMAL STROMAL CELLS; MIGRATION;

BONE MARROW CELLS; CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CHEMOKINES; COLLAGENASES; ETHYLENEDIAMINES; HUMANS; IMMUNOSUPPRESSION; MESENCHYMAL STROMAL CELLS; PEPTIDE HYDROLASES;

EID: 84895820780     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2013.10.003     Document Type: Article

References (42)

1. Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
2. Jiang Y., Jahagirdar B.N., Reinhardt R.L., Schwartz R.E., Keene C.D., Ortiz-Gonzalez X.R., et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002, 418:41-49.
3. Lee K.D., Kuo T.K., Whang-Peng J., Chung Y.F., Lin C.T., Chou S.H., et al. In vitro hepatic differentiation of human mesenchymal stem cells. Hepatology 2004, 40:1275-1284.
4. Brazelton T.R., Rossi F.M., Keshet G.I., Blau H.M. From marrow to brain: expression of neuronal phenotypes in adult mice. Science 2000, 290:1775-1779.
5. Oswald J., Boxberger S., Jorgensen B., Feldmann S., Ehninger G., Bornhauser M., et al. Mesenchymal stem cells can be differentiated into endothelial cells in vitro. Stem Cells 2004, 22:377-384.
6. Uccelli A., Moretta L., Pistoia V. Mesenchymal stem cells in health and disease. Nature Rev Immunol 2008, 8:726-736.
7. Ding Y., Xu D., Feng G., Bushell A., Muschel R.J., Wood K.J. Mesenchymal stem cells prevent the rejection of fully allogenic islet grafts by the immunosuppressive activity of matrix metalloproteinase-2 and -9. Diabetes 2009, 58:1797-1806.
8. Ren G., Zhang L., Zhao X., Xu G., Zhang Y., Roberts A.I., et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008, 2:141-150.
9. Nemeth K., Leelahavanichkul A., Yuen P.S., Mayer B., Parmelee A., Doi K., et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nature Med 2009, 15:42-49.
10. Le Blanc K., Frassoni F., Ball L., Locatelli F., Roelofs H., Lewis I., et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008, 371:1579-1586.
11. Secchiero P., Zorzet S., Tripodo C., Corallini F., Melloni E., Caruso L., et al. Human bone marrow mesenchymal stem cells display anti-cancer activity in SCID mice bearing disseminated non-Hodgkin's lymphoma xenografts. PloS One 2010, 5:e11140.
12. Jung K.H., Song S.U., Yi T., Jeon M.S., Hong S.W., Zheng H.M., et al. Human bone marrow-derived clonal mesenchymal stem cells inhibit inflammation and reduce acute pancreatitis in rats. Gastroenterology 2011, 140:998-1008.
13. Lin H., Xu R., Zhang Z., Chen L., Shi M., Wang F.S. Implications of the immunoregulatory functions of mesenchymal stem cells in the treatment of human liver diseases. Cell Mol Immunol 2011, 8:19-22.
14. Amado L.C., Saliaris A.P., Schuleri K.H., St John M., Xie J.S., Cattaneo S., et al. Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction. Proc Natl Acad Sci U S A 2005, 102:11474-11479.
15. Aldridge V., Garg A., Davies N., Bartlett D.C., Youster J., Beard H., et al. Human mesenchymal stem cells are recruited to injured liver in a beta1-integrin and CD44 dependent manner. Hepatology 2012, 56:1063-1073.
16. Ley K., Laudanna C., Cybulsky M.I., Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 2007, 7:678-689.
17. Thankamony S.P., Sackstein R. Enforced hematopoietic cell E- and L-selectin ligand (HCELL) expression primes transendothelial migration of human mesenchymal stem cells. Proc Natl Acad Sci U S A 2011, 108:2258-2263.
18. Sarkar D., Vemula P.K., Zhao W., Gupta A., Karnik R., Karp J.M. Engineered mesenchymal stem cells with self-assembled vesicles for systemic cell targeting. Biomaterials 2010, 31:5266-5274.
19. Wu Y., Zhao R.C. The role of chemokines in mesenchymal stem cell homing to myocardium. Stem Cell Rev 2012, 8:243-250.
20. Karp J.M., Leng Teo G.S. Mesenchymal stem cell homing: the devil is in the details. Cell Stem Cell 2009, 4:206-216.
21. Chamberlain G., Smith H., Rainger G.E., Middleton J. Mesenchymal stem cells exhibit firm adhesion, crawling, spreading and transmigration across aortic endothelial cells: effects of chemokines and shear. PloS One 2011, 6:e25663.
22. Ji J.F., He B.P., Dheen S.T., Tay S.S. Interactions of chemokines and chemokine receptors mediate the migration of mesenchymal stem cells to the impaired site in the brain after hypoglossal nerve injury. Stem Cells 2004, 22:415-427.
23. Ciuculescu F., Giesen M., Deak E., Lang V., Seifried E., Henschler R. Variability in chemokine-induced adhesion of human mesenchymal stromal cells. Cytotherapy 2011, 13:1172-1179.
24. Ponte A.L., Marais E., Gallay N., Langonne A., Delorme B., Herault O., et al. The in vitro migration capacity of human bone marrow mesenchymal stem cells: comparison of chemokine and growth factor chemotactic activities. Stem Cells 2007, 25:1737-1745.
25. Sordi V., Malosio M.L., Marchesi F., Mercalli A., Melzi R., Giordano T., et al. Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets. Blood 2005, 106:419-427.
26. Ringe J., Strassburg S., Neumann K., Endres M., Notter M., Burmester G.R., et al. Towards in situ tissue repair: human mesenchymal stem cells express chemokine receptors CXCR1, CXCR2 and CCR2, and migrate upon stimulation with CXCL8 but not CCL2. J Cell Biochem 2007, 101:135-146.
27. Lubis A.M., Sandhow L., Lubis V.K., Noor A., Gumay F., Merlina M., et al. Isolation and cultivation of mesenchymal stem cells from iliac crest bone marrow for further cartilage defect management. Acta Medica Indonesiana 2011, 43:178-184.
28. Faint J.M., Tuncer C., Garg A., Adams D.H., Lalor P.F. Functional consequences of human lymphocyte cryopreservation: implications for subsequent interactions of cells with endothelium. J Immunother 2011, 34:588-596.
29. Zhao W., Li J.J., Cao D.Y., Li X., Zhang L.Y., He Y., et al. Intravenous injection of mesenchymal stem cells is effective in treating liver fibrosis. World J Gastroenterol 2012, 18:1048-1058.
30. Loebinger M.R., Eddaoudi A., Davies D., Janes S.M. Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer. Cancer Res 2009, 69:4134-4142.
31. Niess H., Bao Q., Conrad C., Zischek C., Notohamiprodjo M., Schwab F., et al. Selective targeting of genetically engineered mesenchymal stem cells to tumor stroma microenvironments using tissue-specific suicide gene expression suppresses growth of hepatocellular carcinoma. Ann Surg 2011, 254:767-774.
32. Wagner W., Feldmann R.E., Seckinger A., Maurer M.H., Wein F., Blake J., et al. The heterogeneity of human mesenchymal stem cell preparations: evidence from simultaneous analysis of proteomes and transcriptomes. Exp Hematol 2006, 34:536-548.
33. Heng B.C., Cowan C.M., Basu S. Comparison of enzymatic and non-enzymatic means of dissociating adherent monolayers of mesenchymal stem cells. Biological Procedures Online 2009, 11:161-169.
34. Batista U., Garvas M., Nemec M., Schara M., Veranic P., Koklic T. Effects of different detachment procedures on viability, nitroxide reduction kinetics and plasma membrane heterogeneity of V-79 cells. Cell Biol Int 2010, 34:663-668.
35. Schweichel J.U., Merker H.J. The morphology of various types of cell death in prenatal tissues. Teratology 1973, 7:253-266.
36. Levine B., Yuan J. Autophagy in cell death: an innocent convict?. J Clin Invest 2005, 115:2679-2688.
37. Bhogal R.H., Weston C.J., Curbishley S.M., Adams D.H., Afford S.C. Autophagy: a cyto-protective mechanism which prevents primary human hepatocyte apoptosis during oxidative stress. Autophagy 2012, 8:545-558.
38. Lock R., Debnath J. Extracellular matrix regulation of autophagy. Curr Opin Cell Biol 2008, 20:583-588.
39. Fung C., Lock R., Gao S., Salas E., Debnath J. Induction of autophagy during extracellular matrix detachment promotes cell survival. Mol Biol Cell 2008, 19:797-806.
40. Wynn R.F., Hart C.A., Corradi-Perini C., O'Neill L., Evans C.A., Wraith J.E., et al. A small proportion of mesenchymal stem cells strongly expresses functionally active CXCR4 receptor capable of promoting migration to bone marrow. Blood 2004, 104:2643-2645.
41. Chamberlain G., Wright K., Rot A., Ashton B., Middleton J. Murine mesenchymal stem cells exhibit a restricted repertoire of functional chemokine receptors: comparison with human. PloS One 2008, 3:e2934.
42. Loetscher P., Pellegrino A., Gong J.H., Mattioli I., Loetscher M., Bardi G., et al. The ligands of CXC chemokine receptor 3, I-TAC, Mig, and IP10, are natural antagonists for CCR3. J Biol Chem 2001, 276:2986-2991.